Neurological symptoms and axonal damage in COVID-19 survivors: are there sequelae?

The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunologic research Jg. 69; H. 6; S. 553 - 557
Hauptverfasser: Bozzetti, Silvia, Ferrari, Sergio, Zanzoni, Serena, Alberti, Daniela, Braggio, Michele, Carta, Sara, Piraino, Francesco, Gabbiani, Daniele, Girelli, Domenico, Nocini, Riccardo, Monaco, Salvatore, Crisafulli, Ernesto, Mariotto, Sara
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New York Springer US 01.12.2021
Springer Nature B.V
Schlagworte:
Adult
Aged
Aged, 80 and over
Ageusia - pathology
Ageusia - virology
Allergology
Anosmia - pathology
Anosmia - virology
Axons - pathology
Axons - virology
Biomedical and Life Sciences
Biomedicine
Coronaviruses
COVID-19
COVID-19 - pathology
Disease Progression
Fatigue - pathology
Fatigue - virology
Female
Humans
Immunology
Internal Medicine
Italy
Male
Medicine/Public Health
Memory Disorders - pathology
Memory Disorders - virology
Middle Aged
Myalgia
Myalgia - pathology
Myalgia - virology
Nervous System Diseases - pathology
Nervous System Diseases - virology
Neurofilament Proteins - blood
Neurological complications
Olfaction disorders
Original
Original Article
Patients
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Italy
COVID-19
Neurofilament
SARS-CoV-2
Hypogeusia
NfL
Hyposmia
ISSN:0257-277X, 1559-0755, 1559-0755
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The persistence of neurological symptoms after SARS-CoV-2 infection, as well as the presence of late axonal damage, is still unknown. We performed extensive systemic and neurological follow-up evaluations in 107 out of 193 consecutive patients admitted to the COVID-19 medical unit, University Hospital of Verona, Italy between March and June 2020. We analysed serum neurofilament light chain (NfL) levels in all cases including a subgroup ( n  = 29) of patients with available onset samples. Comparisons between clinical and biomarker data were then performed. Neurological symptoms were still present in a significant number ( n  = 49) of patients over the follow-up. The most common reported symptoms were hyposmia ( n  = 11), fatigue ( n  = 28), myalgia ( n  = 14), and impaired memory ( n  = 11) and were more common in cases with severe acute COVID-19. Follow-up serum NfL values (15.2 pg/mL, range 2.4–62.4) were within normal range in all except 5 patients and did not differentiate patients with vs without persistent neurological symptoms. In patients with available onset and follow-up samples, a significant ( p  < 0.001) decrease of NfL levels was observed and was more evident in patients with a severe acute disease. Despite the common persistence of neurological symptoms, COVID-19 survivors do not show active axonal damage, which seems a peculiar feature of acute SARS-CoV-2 infection.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0257-277X
1559-0755
1559-0755
DOI:10.1007/s12026-021-09220-5